准多巴胺载体以改善阿尔茨海默氏症患者的认知缺陷
Ammara Shaikh1, Fairus Ahmad1, Seong Lin Teoh1
1Department of Anatomy, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.
Frontiers in cellular neuroscience
|November 29, 2023
概括
阿尔茨海默病涉及影响认知和行为的大脑变化. 针对多巴胺载体提供了一个有前途的策略,以改善认知功能,并解决阿尔茨海默病中多巴胺系统功能障碍.
科学领域:
- 神经科学是一个神经科学.
- 神经退行性疾病 神经退行性疾病
- 多巴胺基系统研究 研究 多巴胺基系统研究
背景情况:
- 阿尔茨海默病 (AD) 病理包括粉样蛋白和神经纤维状,导致神经元损伤和认知/行为缺陷.
- 多巴氨基系统功能障碍导致神经退行性疾病 (如AD和帕金森病) 的认知和运动障碍.
- 虽然多巴胺神经元,受体和水平在阿尔茨海默病中得到了研究,但外皮拉米德症状仍然不完全理解.
研究的目的:
- 探索多巴胺基系统在阿尔茨海默病中的作用.
- 研究多巴胺载体作为AD治疗点的潜力.
- 为了解决阿尔茨海默病的认知和多巴胺缺陷.
主要方法:
- 对阿尔茨海默氏症中多巴胺基系统的现有研究进行了审查.
- 分析多巴胺载体在认知功能中的作用.
- 探索针对多巴胺载体的治疗策略.
主要成果:
- 多巴氨基系统在阿尔茨海默病中观察到的认知和行为变化中起着重要作用.
- 多巴胺转运体,一个以前被忽视的组成部分,显示出作为一个关键目标的潜力.
- 准多巴胺载体可能提供一种新的方法来增强AD的认知能力.
结论:
- 多巴胺转运体是改善阿尔茨海默病认知缺陷的有希望的治疗标.
- 对多巴胺载体的进一步研究可以阐明AD中多巴胺功能障碍的机制.
- 调节多巴胺载体可能有助于解决阿尔茨海默病中更广泛的多巴胺系统功能障碍.
相关概念视频
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:26Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
128
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
128
01:24Parkinson's Disease: Treatment
276
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
276
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K